Publication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015
March 27 2015 - 2:40PM
Galapagos NV (Euronext:GLPG) has the honor
to invite the Shareholders, Warrant Holders, Directors and
Statutory Auditor of the Company to the Annual Shareholders'
Meeting that will be held on Tuesday 28 April 2015 at 2:00 p.m.
(CET) at the registered office of the Company.
In order to be admitted to the Shareholders'
Meeting, the holders of securities issued by the Company must
comply with article 536 of the Belgian Companies Code and article
29 of the articles of association of the Company, and fulfill the
formalities and make the notifications described in the convening
notice.
The Annual Report 2014, convening notice, and other relevant
documents can be found at
http://www.glpg.com/index.php/companyoverview/shareholder-information/shareholder-meetings/
About Galapagos
Galapagos (Euronext:GLPG) (OTC:GLPYY) is a
clinical-stage biotechnology company specialized in the discovery
and development of small molecule medicines with novel modes of
action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 25 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, and other indications. In the field of
inflammation, AbbVie and Galapagos signed a collaboration agreement
for the development and commercialization of filgotinib.
Filgotinib is an orally-available, selective inhibitor of JAK1 for
the treatment of rheumatoid arthritis and potentially other
inflammatory diseases, currently in Phase 2B studies in RA and in
Phase 2 in Crohn's disease. GLPG1205, a first-in-class
inhibitor of GPR84, is currently being tested in a Phase 2
proof-of-concept trial in ulcerative colitis patients.
GLPG1690, a first-in-class inhibitor of autotaxin, has shown
favorable safety in a Phase 1 trial and is expected to enter Phase
2 in idiopathic pulmonary fibrosis. AbbVie and Galapagos also
signed a collaboration agreement in cystic fibrosis to develop and
commercialize molecules that address mutations in the CFTR
gene. Potentiator GLPG1837 is currently in a Phase 1 trial,
and corrector GLPG2222 is at the pre-clinical candidate
stage. The Galapagos Group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including,
without limitation, expectations regarding the commercial potential
of our product candidates generally, all of which involve certain
risks and uncertainties. These statements are often, but are
not always, made through the use of words or phrases such as
"believes," "anticipates," "expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could," "stands to," "continues," "we
believe," "we intend," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Among the factors that may result in differences
are the inherent uncertainties associated with competitive
developments, clinical trial and product development activities,
regulatory approval requirements and estimating the commercial
potential of our product candidates. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based, unless required by law or
regulation.
HUG#1906958
CONTACT: Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024